分化型甲状腺癌术后131I治疗的必要性

目的比较分化型甲状腺癌(DTC)手术切除后单纯T4抑制治疗与131I治疗联合T4抑制治疗的生存率与复发率,证明DTC术后131I治疗的必要性。方法232例DTC病例分为A组:手术切除后T4抑制治疗(n=108),B组:手术切除后联合131I治疗联合T4抑制治疗(n=124)。根据寿命法分别统计两组无死亡生存率、无复发生存率、无进展生存率和无疾病生存率。各组和各生存率间采用F检验作两两比较。结果A组病例在手术后1、5、10年的复发率分别为4.63%、8.33%和12.04%,B组为0.81%、4.03%和7.26%。A组半数病例复发时间为2年,而B组为4年。两组在无复发生存率、无进展生存率和无疾病生存率比较上,B组明显优于A组。结论DTC患者手术切除后即行131I治疗是预防和治疗、复发或转移的最佳治疗方法。

Necessity of Postoperative 131I Treatment for Differentiated Thyroid Carcinoma

Objective To compare the surgical resection T_(4) inhibition therapy and surgical resection ~(131)I T_(4)inhibition therapy for differentiated thyroid cancer(DTC) in survival rate and recurrence rate,and to prove the necessity of postoperative ~(131)I treatment. Methods Two hundred and thirty-two patients were divided into two groups: group A,n=108,surgical resection T_(4) inhibition therapy;group B,n=124,surgical resection ~(131)I T_(4) inhibition therapy. Survival rate,non-recurrence survival rate,non-progression survival rate and healthy suvival rate were statistically calculated and comparisons were made by F test. Results The 1-,5-,and 10-year postoperative recurrence rate were 4.63%,8.33% and 12.04%,respectively in group A and 0.81%,4.03% and 7.26%,respectively in group B.Fifty-percent-recurrence time was 2 years in group A and 4 years in group B.Group B performed significantly better in non-recurrence survival rate,non-progression survival rate and healthy suvival rate.(Conclusion)Postoperative ~(131)I treatment may be the best measure to prevent the recurrence and metastasis for DTC.